Overview
- Lupin said its wholly owned unit Nanomi BV signed a definitive deal to buy Amsterdam‑headquartered VISUfarma for an enterprise value of €190 million, funded from existing cash.
- The acquisition is positioned to broaden Lupin’s specialty presence in ophthalmology and provide a direct commercial footprint across major European markets.
- VISUfarma reported about €48 million in 2024 revenue and markets more than 60 branded eye‑care products across Italy, the UK, Spain, Germany and France.
- The transaction is expected to be accretive to growth and margins and remains subject to customary approvals, including German foreign‑investment clearance and a notification in Spain.
- Market reaction was modest, and advisers include Centerview Partners for Lupin and Stifel for GHO Capital, VISUfarma’s seller.